Biocad against Roche
A well-known Russian pharma company Biocad brings an action against the Swiss Roche.
In its claim brought to the Federal Court of New York it is said that Roch violaes the antimonopoly legislation using its position as the sole manufacturer of original drugs Avastin, Herceptin and Rituxan, intended for treatment of cancer patients. The company overvalues these drugs in the USA, while undercutting prices in Russia. Roche suffers losses, but makes it to keep the Russian manufacturer from launching its generics in the Russian market.
The fact is that exclusive rights of Roche for the above drugs expire in 201802019. Any delay in Russian generic manufacture launch will be profitable for the Swiss company. As soon as they are manufactured locally, sales of Swiss drugs will stop.
The decision rests with the court.